EA201892757A1 - Антитело, проникающее в цитозоль, и его применение - Google Patents

Антитело, проникающее в цитозоль, и его применение

Info

Publication number
EA201892757A1
EA201892757A1 EA201892757A EA201892757A EA201892757A1 EA 201892757 A1 EA201892757 A1 EA 201892757A1 EA 201892757 A EA201892757 A EA 201892757A EA 201892757 A EA201892757 A EA 201892757A EA 201892757 A1 EA201892757 A1 EA 201892757A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cytosol
exit
variable
antibody
application
Prior art date
Application number
EA201892757A
Other languages
English (en)
Inventor
Ён Сон КИМ
Чи Сун Ким
Чи Ён Пак
Original Assignee
Орум Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орум Терапьютикс Инк. filed Critical Орум Терапьютикс Инк.
Priority claimed from PCT/KR2017/005559 external-priority patent/WO2017204606A1/ko
Publication of EA201892757A1 publication Critical patent/EA201892757A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее раскрытие относится к антителу, проникающему в цитозоль, и его применению и, более конкретно, к идентификации структурного механизма, который индуцирует выход из эндосомы в цитозоль после клеточной интернализации в живых клетках через белок клеточной мембраны, к вариабельному участку легкой цепи и/или вариабельному участку тяжелой цепи, которые основаны на этой идентификации и имеют значительно улучшенную способность к выходу из эндосом в цитозоль, к включающему их антителу, проникающему в цитозоль, к способу его получения и к его применению.
EA201892757A 2017-05-26 2017-05-26 Антитело, проникающее в цитозоль, и его применение EA201892757A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170065670A KR20180129514A (ko) 2017-05-26 2017-05-26 세포질 침투 항체 및 이의 용도
PCT/KR2017/005559 WO2017204606A1 (ko) 2016-05-27 2017-05-26 세포질 침투 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
EA201892757A1 true EA201892757A1 (ru) 2019-07-31

Family

ID=64744205

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892757A EA201892757A1 (ru) 2017-05-26 2017-05-26 Антитело, проникающее в цитозоль, и его применение

Country Status (2)

Country Link
KR (1) KR20180129514A (ru)
EA (1) EA201892757A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102154177B1 (ko) * 2019-01-15 2020-09-09 충남대학교 산학협력단 세포질 침투성이 증진된 항체의 스크리닝 방법
KR20200088780A (ko) * 2019-01-15 2020-07-23 오름테라퓨틱 주식회사 세포질 침투성이 증진된 항체
JP2023512709A (ja) * 2020-02-06 2023-03-28 アジュ ユニバーシティー インダストリー－アカデミック コーオペレイション ファウンデーション 抗原由来ｔ細胞抗原エピトープ又はこれを含むペプチドを細胞表面に提示するための融合抗体、及びこれを含む組成物

Also Published As

Publication number Publication date
KR20180129514A (ko) 2018-12-05

Similar Documents

Publication Publication Date Title
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
MX2020001879A (es) Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
CY1120471T1 (el) Αντισωματα κατα του cd70
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CO2018005436A2 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
MX2018014554A (es) Anticuerpo penetrante de citosol y uso del mismo.
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201892774A1 (ru) Антитела
EA202090399A1 (ru) Системы и способы для подготовки в режиме реального времени образца полипептида для анализа с помощью масс-спектрометрии
EA201892757A1 (ru) Антитело, проникающее в цитозоль, и его применение
CO2017000558A2 (es) Variantes de proteínas de unión al factor h
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
WO2016023898A3 (en) Intracellular antigen binding
EA201992027A1 (ru) Водный состав антитела против pd-l1
EA201990758A1 (ru) Способ получения электрокомпетентных дрожжевых клеток и способ применения указанных клеток
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
EA201990218A1 (ru) Антитела с низкой иммуногенностью и их применения